Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
10.73
+1.21 (12.71%)
At close: Jun 26, 2026, 4:00 PM EDT
10.90
+0.17 (1.58%)
After-hours: Jun 26, 2026, 7:53 PM EDT

Akari Therapeutics, Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
1201112
Market Cap Growth
-69.46%-59.68%57.15%-41.00%-50.99%0.31%
Enterprise Value
10.25-4.121.47-3.33-12.38-7.58
Last Close Price
10.730.291.223.129.4030.00
PB Ratio
0.850.010.04-2.250.170.22
P/TBV Ratio
----0.140.20
EV/EBITDA Ratio
-0.24-0.20-0.44
EV/EBIT Ratio
-0.24-0.20-0.44
EV/FCF Ratio
-0.39-0.701.620.40
Debt / Equity Ratio
0.050.030.14000
Net Debt / Equity Ratio
-0.14-0.160.0316.79-2.53-1.13
Net Debt / EBITDA Ratio
0.070.26-0.030.23-0.540.54
Net Debt / FCF Ratio
0.190.42-0.050.811.740.50
Quick Ratio
0.210.420.130.842.062.35
Current Ratio
0.270.440.150.952.062.35
Return on Equity (ROE)
-38.85%-68.43%-179.92%-399.52%-251.90%-168.82%
Return on Assets (ROA)
-72.16%-33.17%-78.82%-163.38%169.91%-107.74%
Return on Invested Capital (ROIC)
-78.25%-34.14%-81.16%-364.16%371.51%-356.59%
Return on Capital Employed (ROCE)
-105.36%-52.20%-142.28%-413.08%287.27%-133.12%
Buyback Yield / Dilution
-143.97%-70.22%-443.34%-56.79%-45.46%-35.87%
Total Shareholder Return
-143.97%-70.22%-443.34%-56.79%-45.46%-35.87%
SEC Filings: 10-K · 10-Q